Skip to main content

Table 1 Criteria for registry participants

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Inclusion
• Patients with a diagnosis of chronic hypoparathyroidism and with a duration of ≥6 months
 – Adult patients aged ≥18 years who are receiving conventional therapy, conventional therapy plus rhPTH(1-84), or rhPTH(1-84) alone
 – Pediatric patients aged <18 years who are receiving conventional therapy, conventional therapy plus rhPTH(1-84), or rhPTH(1-84) alone
Exclusion
• Patients or legally authorized representatives unable to provide informed consent
• Patients using rhPTH(1-34), or used rhPTH(1-34) for >2 years and in the past 3 months
• Patients currently enrolled in an interventional clinical study whether or not the study is related to hypoparathyroidisma
• History of hypoparathyroidism resulting from a known activating mutation in the CASR gene
• History of hypoparathyroidism resulting from impaired responsiveness to PTH (pseudohypoparathyroidism)
  1. PTH parathyroid hormone, rhPTH(1-34) recombinant human parathyroid hormone (1-34), rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aDoes not apply to those enrolled in other observational registries. The criteria were added during amendments to the original protocol to account for the inclusion of registry participants treated with rhPTH(1-84) prior to registry enrollment